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Abstract Accumulation of lipid-loaded macrophages
(foam cells) within the vessel wall is an early hallmark of
atherosclerosis. High-density lipoproteins (HDL) and apo-
lipoprotein A-I (apoA-I) can efficiently promote cholesterol
efflux from macrophages. Therefore, the interaction of
HDL and apoA-I with macrophages appears to be important
in the initial steps of reverse cholesterol transport, i.e. the
transport of excess cholesterol from foam cells to the liver.
However, although several cellular apoA-I and HDL
receptors and transporters have been identified, it is as yet
controversial how these interactions lead to cholesterol
efflux from foam cells. In this study, we show that
RAW264.7 macrophages bind HDL and apoA-I in a
competable manner. Furthermore, cell surface biotinylation
experiments revealed that apoA-I but not HDL is specifi-
cally internalised. Binding of HDL to macrophages is
decreased by reducing the expression of scavenger receptor
BI (SR-BI) with cyclic adenosine monophosphate (cAMP),
acetylated low-density lipoprotein (acLDL) or RNA inter-
ference. In contrast, apoA-I cell association and internal-
isation is modulated in parallel with ATP-binding cassette
transporter A1 (ABCA1) expression which is altered by
stimulating cells with cAMP and acLDL or expressing
short hairpin RNA (shRNA) against ABCA1. Consistent
with this, cell surface trapping of ABCA1 with cyclosporin
A (CsA) results in increased apoA-I binding but reduced
internalisation. Furthermore, blocking apoA-I uptake inhib-
its cholesterol efflux to apoA-I but not to HDL. Taken
together, these data suggest that apoA-I- but not HDL-
mediated cholesterol efflux may involve retroendocytosis.
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Introduction
Atherosclerosis is a progressive inflammatory disease that is
characterised by the accumulation of lipids and fibrous
elements within the wall of arteries [1]. Monocyte-derived
macrophages are key players of both initiation and progres-
sion of atherosclerosis. Early in the development of athero-
sclerotic lesions, monocytes attach to endothelial cells and
transmigrate into the subendothelial space where they can
differentiate into macrophages [2]. The uncontrolled uptake
of modified lipoproteins by macrophages via scavenger
receptors leads to the accumulation of cholesteryl esters and
the formation of macrophage-derived foam cells. This im-
balance in cholesterol homeostasis is considered as an
important step in the pathogenesis of atherosclerosis. Plasma
levels of high-density lipoproteins (HDL) and their major
protein constituent apolipoprotein A-I (apoA-I) are inversely
correlated with the risk of atherosclerosis [3]. Among
various atheroprotective properties of HDL and apoA-I, they
serve as acceptor particles for macrophage cholesterol efflux,
thereby initiating reverse cholesterol transport [4, 5]. For
many years, the efflux of cholesterol was thought to occur
primarily by passive aqueous diffusion, but recently it has
become clear that this process is highly regulated and medi-
ated by specific transporters and receptors including ATP-
binding cassette transporter A1 (ABCA1) and scavenger
receptor BI (SR-BI).
ABCA1 facilitates efflux of cellular phospholipids and
cholesterol to lipid-poor apoA-I. Mutations in the ABCA1
gene are the underlying cause of Tangier disease [6–8], which
is characterised by very low levels of plasma HDL, accumu-
lation of cholesterol in tissue macrophages and moderately
accelerated atherosclerosis. Mice with a targeted knock-out
of ABCA1 in macrophages show enhanced atherosclerosis
[9–11]. These data demonstrate the physiological importance
of ABCA1 for cholesterol efflux. However, the molecular
mechanism by which ABCA1 accomplishes cholesterol
efflux is not yet resolved. Evidence is accumulating that
lipid efflux requires physical interactions between apoA-I
and ABCA1 [12–16], but it is not known whether this is a
pure cell-surface event or involves the internalisation of
apoA-I (reviewed in [17]).
In addition to ABCA1, SR-BI also promotes cholesterol
efflux from macrophages, however to mature lipidated
HDL rather than to lipid-poor apoA-I. SR-BI was originally
characterised for its ability to mediate selective uptake of
cholesteryl esters, phospholipids and triglycerides from
HDL and other lipoproteins into liver and steroidogenic
cells without whole-particle uptake [18]. However, SR-BI
can also mediate bidirectional flux of cholesterol between
macrophages and HDL [19]. Indeed, SR-BI-deficient mice
as well as mice specifically lacking macrophage SR-BI
show increased atherosclerosis [20–22]. However, although
it is well accepted that the lipoprotein–macrophage inter-
action protects against foam cell formation and contributes
to the prevention of atherosclerosis, the molecular mecha-
nisms underlying this interaction are still not known.
In the present study, we investigated the interaction of
HDL and apoA-I with macrophages to gain insight into the
mechanism finally leading to cholesterol efflux. In contrast
to other studies in this field, we directly compared the
interaction of apoA-I and HDL within one well-defined cell
system, namely, RAW264.7 cells. Thereby, we obtained
evidence that ABCA1-dependent cholesterol efflux to apoA-I
but not SR-BI-dependent cholesterol efflux to HDL requires
internalisation of the agonist.
Materials and methods
Cell culture
The macrophage cell line RAW264.7 was obtained from the
American Type Culture Collection and cultured in regular
tissue culture dishes in Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma) supplemented with 10% fetal calf serum
at 37°C in a humidified 5% CO2, 95% air incubator.
Isolation and labelling of HDL and apoA-I
Plasma HDL (1.063<d<1.21 g/ml) was isolated from fresh
normolipidemic human plasma of blood donors by sequen-
tial ultracentrifugation [23]. The purity of the lipoprotein
preparation was verified by apolipoprotein composition
analysis in a 10% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) to exclude contaminations
with low-density lipoprotein (LDL) or albumin. HDL was
iodinated with Na125I by the McFarlane monocholoride
procedure as modified for lipoproteins [24]. Specific
activities of approximately 300–900 cpm/ng of protein
were obtained. Lipid-free human apoA-I was further
extracted from HDL as described previously [25]. ApoA-I
was labelled with 125I using Iodo-Beads iodination reagent
(Pierce) and Na125I, according to the manufacturer’s
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instructions. Specific activities of 600–1,200 cpm/ng pro-
tein were obtained.
Binding and cell association
Cells were seeded in 12-well dishes at a concentration of
5×105 cells/well and grown until confluence (2 days). After
washing the cells twice with DMEM, they were incubated
for 2 h (or for the indicated time periods) at 4°C (binding)
or 37°C (cell association) in DMEM/25 mM Hepes/1%
bovine serum albumin (BSA) containing 5 μg/ml 125I-apoA-I
or 10 μg/ml 125I-HDL, in the absence (total binding) or in
the presence (unspecific binding) of a 40-fold excess of
unlabeled apoA-I or HDL (or the indicated competitor).
After incubation, cells were washed three times with cold
phosphate-buffered saline (PBS) containing 0.1 mM CaCl2
and 1 mM MgCl2. Cells were then lysed in 0.5 ml radio-
immunoprecipitation assay (RIPA) buffer [10 mM Tris
pH 7.4, 150 mM NaCl, 1% NP-40, 1% sodium deoxycho-
late, 0.1% SDS, complete protease inhibitor (Roche)]. The
amount of bound radioactivity was determined using a γ-
counter and normalised to the total protein content.
Cell surface biotinylation and internalisation
The assay was performed as described above for binding
and cell association studies. After incubation with 125I-
apoA-I and 125I-HDL, the cells were washed as described
earlier and chilled on ice for 15 min. Cell surface proteins
were biotinylated at 4°C for 1 h using 500 μg/ml EZ-link-
sulfo-NHS-LC-biotin (Pierce) in PBS containing 0.1 mM
CaCl2 and 1 mM MgCl2. After biotinylation, the PBS was
saved, and radioactivity was measured and added to the
amount of cell surface-bound protein measured later on.
The reaction was stopped by 5 min incubation in DMEM.
Cells were lysed in 0.5 ml RIPA buffer, and the lysates
were incubated overnight at 4°C with 25 μl of 50%
streptavidin-conjugated sepharose bead slurry (GE Health-
care) The biotinylated cell surface proteins were pulled
down and thereby separated from not biotinylated internal
proteins. The radioactive counts of the supernatant contain-
ing the internal proteins were measured and normalised to
the protein contents.
Immunofluorescence microscopy
RAW264.7 cells were seeded in 24-well dishes and grown
on coverslips until confluence. After washing the cells
twice with DMEM, they were incubated for 2 h at 4 or 37°C
in DMEM/25 mM Hepes/1% BSA containing 5 μg/ml
apoA-I labelled with flourescein isothiocyanate (FITC)
(Pierce). Thereafter, the cells were washed three times with
PBS, fixed in 3% parformaldehyde and washed again with
PBS. Cells were mounted in mounting media containing
ProLong Antifade agents (Molecular Probes). Confocal
microscopy and differential interference contrast microscopy
was performed with a 63× oil-immersion lens.
SR-BI siRNA transfection
RAW264.7 cells were transfected with 67 nM BLOCK-
iT™ fluorescent oligo only (noncoding) or in combination
with 100 nM Stealth siRNA (both Invitrogen) against mSR-
BI (5′-GGCTATGACGATCCCTTCGTGCATT-3′) with
Lipofectamine 2000 in OPTIMEM (Invitrogen), according
to the manufacturer’s protocol. Six hours after transfection,
the medium was replaced by DMEM 10% FCS without
antibiotics. Binding, cell association and internalisation
assays were performed 24 h after transfection. The
efficiency of the silencing was evaluated by quantitative
real-time polymerase chain reaction (RT-PCR) and Western
blotting.
ABCA1 short hairpin RNA expressing plasmid
and cell transfection
The plasmid expressing short hairpin RNA (shRNA)
against mABCA1 was prepared using the GeneClip™ U1
Hairpin Cloning System (Promega). Two DNA oligonu-
cleotides containing the hairpin siRNA target sequences
mABCA1_sense 5′-TCTCGACCACCCTGGAAGAAA
TAAAGTTCTCTTATTTCTTCCAGGGTGGTCCT-3′ and
mABCA1_antisense 5′-CTGCAGGACCACCCTGGAA
GAAATAAGAGAACTTTATTTCTTCCAGGGTGGTC-3′
(Microsynth) were cloned into the linearised pGeneClip™
neomycin vector. For stable transfection RAW264.7 cells
were plated in a 6-well plate and transfected with the empty
vector (mock) or with the vector containing the insert with
Lipofectamine 2000. Two days after transfection, the cells
were trypsinised and plated at low density in growth me-
dium containing 1.0 mg/ml G418. Resistant colonies were
picked and expanded. The efficiency of the silencing was
evaluated by quantitative RT-PCR and Western blotting.
Binding studies and cholesterol efflux experiments were
performed in the absence of selective pressure.
Quantitative RT-PCR
Cells were harvested for total RNA using Tri Reagent
according to the manufacturer’s instructions (MRC). To
remove contaminating genomic DNA from RNA, DNase I
digestion (GE Healthcare) with subsequent DNase I in-
activation was performed. Reverse transcription was per-
formed using Superscript II RT (Invitrogen) following the
standard procedure. Quantitative PCR was done with Light-
Cycler FastStart DNA Master SYBR Green-I (Roche). Gene
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specific primers were used as follows: mABCA1 5′-TGCC
CTATGTGCTGTGCGTAG-3′ (forward), 5′-GGTGA
GATTGAAGCCGTCCTC-3′ (reverse), annealing at 58°C,
3 mM MgCl2; mSR-BI 5′-GGAATCCCCATGAACTG-3′
(forward), 5′-AGCCCTTTTTACTACCACTCC-3′ (re-
verse), annealing at 58°C, 3 mM MgCl2. The transcription
levels were normalised to mGAPDH (5′-CGACCCCTTCA
TTGAC-3′ (forward), 5′-TCCACGACATACTCAGCAC-3′
(reverse), annealing at 58°C, 4 mM MgCl2). Data analysis
was performed using the ΔΔCt method.
Western blot
RAW264.7 cells were lysed in RIPA buffer. Equal amounts
of total protein were separated by SDS-PAGE. Alternative-
ly, cell surface proteins were determined by purifying
biotinylated proteins by overnight incubation of 300 μg of
cell proteins with 50 μg streptavidin-conjugated sepharose
beads (GE Healthcare). The beads were washed three times
with lysis buffer, and the pulled-down proteins were loaded
on an SDS-PAGE. Proteins were transblotted onto a poly-
vinylidene fluoride membrane (GE Healthcare). The pro-
teins were identified with the following antibodies: ABCA1
(ab18180, Abcam), SR-BI (ab3, Abcam). Expression levels
were normalised to β-actin (A 5441, Sigma).
Lipid efflux
For cholesterol and phospholipid efflux experiments,
RAW264.7 cells were labelled for 24 h with 2 μCi/ml
[1,2-3H]cholesterol and [methyl-3H]choline chloride (Perkin
Elmer), respectively. After the labelling period, cells were
washed twice with DMEM and were allowed to equilibrate
overnight in DMEM containing 0.2% BSA supplemented
with cholesterol in the presence or absence of 0.3 mM 8-Br-
cyclic adenosine monophosphate (cAMP; Sigma). After 24 h
equilibration, the cells were washed and incubated for 6 h in
DMEM containing 0.2% BSA in the presence or absence of
28 μg/ml lipid-free apoA-I or 100 μg/ml HDL. For some
experiments, the cells were preincubated with 10 μM cyclo-
sporin A (Sigma) 2 h before the assay and during the efflux
period. Efflux media were collected and centrifuged to
remove any detached cells and counted for 3H. The cells
were washed in PBS, lysed in 0.2 M NaOH/0.15 M NaCl
and counted for radioactivity. Fractional cholesterol efflux
was calculated as the percent of total [3H]cholesterol or [3H]
choline released into the medium after subtraction of values
obtained in the absence of apoA-I or HDL.
Statistical analysis
Each experiment shown is a representative of at least three
similar experiments. Data are shown as means±SD. Sta-
tistical analyses were by analysis of variance (ANOVA)
with Dunnett’s multiple comparison post-test (for each
group vs control) or Tukey’s multiple comparison post-test
(for all groups vs each other). All calculations were done
using Prism software (GraphPad, San Diego, CA).
Results
ApoA-I and HDL specifically interact with macrophages
To determine the ability of apoA-I and HDL to function as
ligands for macrophages, RAW264.7 cells were incubated
with radiolabelled lipid-free apoA-I or HDL for 2 h at 4°C
Fig. 1 ApoA-I and HDL are interacting in a specific manner with
macrophages. a RAW264.7 cells were incubated at 4°C (Binding) or
at 37°C (Cell association) for 2 h with 5 μg/ml 125I-apoA-I in the
presence or absence of a 40-fold excess of unlabelled competitor. b
HDL binding and cell association were determined following the same
method as for apoA-I, except that 10 μg/ml 125I-HDL were used.
Single asterisk P<0.05, triple asterisk P<0.001, ns not significantly
different compared with binding/cell association in the absence of a
competitor
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(binding) or 37°C (cell association) in the presence or absence
of a 40-fold excess of unlabelled competitors. ApoA-I binding
and cell association were competed with an excess of apoA-I
or HDL but not with an excess of LDL or BSA (Fig. 1a). HDL
binding and cell association were extensively competed with
an excess of unlabelled HDL, partially with LDL (∼50%) but
not at all with either BSA or, surprisingly, apoA-I (Fig. 1b).
These results indicate that apoA-I and HDL can both interact
specifically with macrophages although in a distinct manner.
ApoA-I but not HDL is internalised in macrophages
Next we analysed the cellular distribution of apoA-I and
HDL in macrophages by using cell-surface biotinylation
assays. RAW264.7 cells were incubated with 125I-apoA-I or
125I-HDL for 2 h at 4°C, a temperature where vesicular
transport is blocked, or at 37°C. After this incubation
period, cell surface-bound proteins were biotinylated at 4°C
and separated from cellular lysate by immunoprecipitation
with streptavidin beads. As shown in Fig. 2a, HDL was
found on the cell surface, and no specific internalisation
could be observed. In contrast to HDL, ∼25% of the total
cell associated apoA-I was found intracellularly (Fig. 2b).
Similar results were also obtained by immunofluorescence
microscopy (Fig. 2b). At 4°C, apoA-I was present at the
cell surface only, whereas at 37°C, apoA-I clustered intra-
cellularly, probably within vesicles in the cells. Further-
more, over time, apoA-I internalisation was increasing at
37°C, reaching saturation after 2 h, whereas at 4°C, as
expected, no increase was observed (Fig. 2d). Upon analysis
by SDS-PAGE, the internalised apoA-I was found intact as a
single band of 28 kDAwas detected (data not shown). Taken
together, these results show that although both HDL and
apoA-I can function as ligands for macrophages, only apoA-I
is specifically internalised.
SR-BI is involved in the interaction of HDL
with macrophages but does not affect the interaction
of apoA-I
SR-BI not only promotes selective uptake of cholesterol
from HDL but has also been shown to bind a variety of
ligands including HDL, LDL and very low density lipopro-
tein (VLDL) [26–28]. Stimulation of RAW264.7 cells with
9-cis-retinoic acid (RA) and/or 22-hydroxycholesterol (22-
HC), two pharmacological agents known to activate liver-
X-receptors (LXRs), slightly reduced SR-BI expression on
the mRNA level but did not affect its expression on the
protein level (Fig. 3a,b). On the other hand, stimulation
with acetylated LDL (acLDL), a modified form of LDL
Fig. 2 ApoA-I but not HDL is
specifically internalised by
macrophages. RAW264.7
cells were incubated with
125I-labelled protein at 4°C
(control) or 37°C for 2 h. Cell-
surface-bound proteins were
biotinylated with 500 μg/ml
biotin and captured with strep-
tavidin beads, whereas not bio-
tinylated proteins were counted
as internal apoA-I or HDL.
a Distribution of 125I-HDL
within the cell. b Distribution
of 125I-apoA-I with the cell after
2 h. c RAW264.7 cells incubat-
ed for 2 h at 4 or 37°C with
5 μg/ml FITC-labelled apoA-I.
Images were analysed by con-
focal or by light differential
interference contrast microscopy
(×63). d Time course of 125I-
apoA-I internalisation. Single
asterisk P<0.05, triple asterisk
P<0.001, ns not significantly
different compared with 4°C
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used to induce foam cell formation, and 8-Br-cAMP, an
analogue of cyclic AMP that induces ABCA1 expression,
reduced SR-BI expression (Fig. 3a,b) and diminished HDL
binding by 40% (Fig. 3c). More direct evidence for the
contribution of SR-BI to HDL binding was obtained by the
use of RNA interference to reduce SR-BI expression. SR-
BI transcription was reduced by 80%, and also the protein
levels were significantly reduced in cells transfected with
SR-BI-specific siRNA in comparison to controls (Fig. 4a,b).
Furthermore, HDL binding was substantially lowered by
more than 60% in siRNA transfected cells (Fig. 4c). We
also investigated the involvement of SR-BI in apoA-I-
binding and cell association. In contrast to HDL, none of
the apoA-I interactions were affected in siRNA transfected
cells compared to control cells (data not shown). The above
experiments thus demonstrate that in RAW264.7 macro-
phages SR-BI modulates HDL binding but has no influence
on apoA-I interactions.
Fig. 3 Effect of SR-BI stimulation on HDL binding. a SR-BI mRNA
and b protein levels were elucidated in cells treated with 10 μM 9-
cis-retinoic acid (RA) or 10 μM 22-(R)-hydroxycholesterol (22-HC) for
24 h, 50 μg/ml acetylated LDL (acLDL) for 48 h, 0.3 mM 8-Br-cAMP
for 16 h. c HDL binding in cells stimulated as in a and b. Single
asterisk P<0.05, double asterisk P<0.01, triple asterisk P<0.001, ns
not significantly different compared with not-stimulated cells
Fig. 4 Suppression of SR-BI expression decreases HDL binding.
RAW264.7 cells were transfected with 100 nM siRNA specific for
mSR-BI. SR-BI silencing was determined after 24 h a on the mRNA
and b on the protein level. As control, noncoding siRNA, mock or not
transfected (NT) cells were used. c HDL binding in siRNA transfected
cells. Double asterisk P<0.01, triple asterisk P<0.001 compared with
noncoding siRNA, mock or not transfected cells
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ABCA1 modulates the binding, cell association
and internalisation of apoA-I but has no effect
on HDL binding
To examine the role of ABCA1 for binding apoA-I and
HDL, RAW264.7 cells expressing shRNA against ABCA1
were used. In these cells, ABCA1 mRNA levels as well as
protein levels were considerably reduced by 50% compared
to control cells (Fig. 5a,b). HDL binding and cell asso-
ciation were identical in cells expressing shRNA against
ABCA1 as well as in mock and not transfected control cells
(data not shown). We then evaluated the interactions of
apoA-I in cells with low ABCA1 expression. As shown in
Fig. 5c and d, cell association and internalisation of apoA-I
were significantly reduced by 40% in cells expressing
shRNA against ABCA1. In addition, although stimulation
with 8-Br-cAMP is known to induce ABCA1 expression in
macrophages [29], apoA-I cell association and internalisation
remained substantially reduced in these cells. Further
evidence for the implication of ABCA1 in apoA-I cell asso-
ciation and internalisation was obtained by experiments done
with cells stimulated with acLDL or 8-Br-cAMP, two treat-
ments known to stimulate ABCA1 expression (Fig. 6a). In
both cases, ABCA1 stimulation was accompanied by
increased apoA-I cell association (Fig. 6b) and internal-
isation (Fig. 6c), indicating that modulation of ABCA1
expression not only affects apoA-I cell association but also
internalisation.
The role of ABCA1 in apoA-I binding and internalisation
was studied in more detail by treating RAW264.7 cells for
4 h with 10 μM cyclosporin A (CsA). As previously re-
ported [30] and shown in Fig. 7a, the 4-h treatment led to a
significant increase in cell surface ABCA1, which was
further enhanced by stimulating the cells with 8-Br-cAMP.
In parallel, binding of apoA-I was doubled after CsA treat-
ment, and this increase was further enhanced by additional
stimulation of the cells with cAMP (Fig. 7b). To exclude that
the observed effect of CsA is ABCA1-independent, we re-
peated the same binding experiment in cells expressing the
vector encoding for shRNA directed against ABCA1
Fig. 5 ABCA1 plays a role in
apoA-I cell association and
internalisation. a Reduction in
ABCA1 expression on the
mRNA and b on the protein
level was determined in cells
stably transfected with a vector
encoding for shRNA against
mABCA1 (shABCA1). As con-
trol, cells transfected with the
empty vector (mock) or not
transfected cells (NT) were
used. c ApoA-I cell association
was measured in cells with low
ABCA1 expression and in
control cells in the presence
or absence of 0.3 mM 8-Br-
cAMP. d ApoA-I internalisation
in cells treated as in c. Single
asterisk P<0.05, triple asterisk
P<0.001, ns not significantly
different compared with mock
or not transfected cells both in
the presence or absence
of 8-Br-cAMP
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(Fig. 7c). As expected, CsA treatment of these cells either in
the absence or in the presence of 8-Br-cAMP did not affect
apoA-I binding. It is interesting to note that apoA-I binding
(Fig. 7b), in contrast to apoA-I cell association (Fig. 7d), was
not significantly increased by stimulation with 8-Br-cAMP
alone. Interestingly, apoA-I cell association (Fig. 7d) and
internalisation (Fig. 7e) were strongly reduced by CsA
treatment in 8-Br-cAMP-stimulated cells. Taken together,
these results clearly demonstrate that ABCA1 plays a role in
apoA-I binding, cell association and internalisation but is not
involved in HDL binding.
Cholesterol efflux to apoA-I is inhibited
when internalisation is reduced
Finally, cholesterol and phospholipid efflux to HDL and
apoA-I were investigated under different conditions. Cho-
lesterol efflux to HDL was doubled in cells stimulated with
8-Br-cAMP but was not altered in cells in which ABCA1
expression was reduced by transfection with shRNA (Fig. 8a).
In contrast, after stimulation with 8-Br-cAMP, cholesterol
efflux to lipid-free apoA-I was enhanced by a factor of 6 and
was reduced in cells with knocked-down ABCA1 expression
(Fig. 8b). This result provides additional evidence for the
crucial role of ABCA1 in cholesterol efflux. To further
elucidate if the reduction in cholesterol efflux was due to
reduced apoA-I internalisation, we added CsA 2 h before the
efflux period and again during the efflux period to inhibit
apoA-I internalisation. Whereas cholesterol efflux from
both unstimulated and 8-Br-cAMP stimulated cells to HDL
remained unaffected by CsA (Fig. 8c), cholesterol efflux to
apoA-I was almost completely inhibited by CsA in 8-
Br-cAMP-stimulated cells (Fig. 8d). CsA also significantly
reduced phospholipid efflux to apoA-I in 8-Br-cAMP stim-
ulated cells (Fig. 8f), although to a lesser extent than
cholesterol efflux. By contrast and like cholesterol efflux,
phosholipid efflux to HDL remained unaffected by CsA
treatment (Fig. 8e). Thus, it seems that ABCA1-dependent
cholesterol and phsopholipid efflux is coupled to apoA-I
internalisation.
Discussion
The role of HDL and its major apolipoprotein apoA-I in
cholesterol efflux from macrophages has been studied exten-
sively, but the molecular details underlying this interaction
are still incompletely understood. In this paper, we directly
compared the interactions of apoA-I and HDL with
RAW264.7 macrophages, a cell system previously evolved
as a well-accepted model for the study of cholesterol homeo-
stasis in macrophages [31, 32]. Furthermore, we investi-
gated the interactions of apoA-I and HDL with ABCA1 and
SR-BI.
Consistent with previously published results, we showed
that macrophages specifically bind HDL and apoA-I [12,
13, 33–35]. Based on competition assays illustrated in
Fig. 1, we observed that while HDL competes for apoA-I
binding, apoA-I is not a competitor for HDL binding. This
observation suggests that HDL and apoA-I are binding to
macrophages at least in part by distinct receptors. For
Fig. 6 ApoA-I cell association and internalisation correlate with
ABCA1 expression. a ABCA1 expression on the protein level was
determined in cells stimulated with 50 μg/ml acetylated LDL (acLDL)
for 48 h or with 0.3 mM 8-Br-cAMP for 16 h. b ApoA-I cell association
in stimulated cells. c apoA-I internalisation in stimulated cells. Single
asterisk P<0.05, double asterisk P<0.01, triple asterisk P<0.001
compared with not-stimulated cells
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example, pre-β-HDL and lipid-free apoA-I are poor ligands
for SR-BI [36], explaining the lack of competition of HDL
binding by apoA-I. Conversely, it has been shown that
apoA-I can dissociate from HDL, so that lipid-free apoA-I
could be available for the competition of the apoA-I bind-
ing site by HDL [37].
While binding experiments performed at 4°C only monitor
the amount of cell surface bound ligands, cell association at
37°C records both cell surface bound and internalised ligands.
In agreement with this is our observation that cell association
is always higher than binding (Fig. 1). Interestingly, this
difference is higher for apoA-I than for HDL, providing
initial evidence for distinct metabolic fates of apoA-I and
HDL. In fact, using cell surface biotinylation assays and
fluorescence microscopy, we were able to demonstrate that
apoA-I but not HDL is internalised by macrophages in a
specific and saturable manner (Fig. 2). Moreover, upon SDS-
PAGE analysis, the internalised apoA-I was found to be
intact rather than degraded (data not shown). Our finding of
apoA-I internalisation is in line with findings of several other
studies which also related this process to cholesterol efflux
[38–41]. The lack of specific HDL internalisation is in
agreement with some previous data [34, 42–45] but also in
contrast to other data demonstrating HDL uptake [46–50].
This difference may reflect differences in cell types or in
methods utilised to investigate uptake. Internalisation assays
require methods that allow distinguishing intracellularly
accumulated particles form particles bound at the cell sur-
Fig. 7 Trapping of ABCA1 on the cell surface increases apoA-I binding
but reduces cell association and internalisation. a Total and cell surface
ABCA1 expression was measured in not-stimulated cells or in cells
stimulated with 0.3 mM 8-Br-cAMP and incubated in the presence or
absence of 10 μM CsA for 4 h. Cell surface proteins were biotinylated
at 4°C and separated from cellular lysate by immunoprecipitation with
streptavidin beads. Total and cell surface ABCA1 were detected by
Western blot analysis. b ApoA-I binding was measured in not-
stimulated cells or in cells stimulated with 0.3 mM 8-Br-cAMP
pretreated or not with 10 μM CsA or 0.05% EtOH (control) for 4 h.
Triple asterisk P<0.001 compared with control cells both in the
presence or absence of 8-Br-cAMP. c ApoA-I binding in shABCA1
cells treated as in b. d ApoA-I cell association in 8-Br-cAMP stimulated
cells in the presence or absence of 10 μM CsA. e ApoA-I internalisation
in cells treated as in d. Single asterisk P<0.05, triple asterisk P<0.001
compared with cells treated in the absence of 8-Br-cAMP, pound sign P
<0.01 compared with cells treated in the presence of 8-Br-cAMP
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face. A commonly used approach is the displacement of
extracellular bound particles with an excess of unlabelled
particles at 4°C [51]. It should be noted that the efficiency to
remove bound particles might be cell dependent and this
could lead to the overestimation of internalised particles. The
advantage of our protocol is that we extracted extracellular
bound particles by exploiting the high affinity interaction
between biotin and streptavidin. Moreover, it is important to
emphasise that our experiments, by contrast to those reported
by most other authors, were performed in parallel on apoA-I
and HDL. Our discrepant findings on these two agonists
strengthen the concept of distinct metabolic fates for apoA-I
and HDL.
Next, we aimed to unravel the receptors modulating the
interactions of HDL and apoA-I with macrophages. SR-BI
is known as the receptor-mediating selective uptake of
cholesterol esters from HDL by the liver and steroidogenic
organs [27, 52]. Moreover, SR-BI is a multi-functional,
multi-ligand receptor that facilitates the binding of a wide
array of native and modified lipoproteins. With respect to
Fig. 8 Cholesterol efflux to
apoA-I but not to HDL is
inhibited when internalisation is
blocked. a Cholesterol efflux to
100 μg/ml HDL for 6 h at 37°C
from RAW264.7 cells stably
expressing shRNA against
ABCA1 or control cells pre-
treated or not with 0.3 mM
8-Br-cAMP to induce ABCA1
expression. b Cholesterol
efflux to 28 μg/ml apoA-I as
described in a for HDL. Triple
asterisk P<0.001 compared
with mock or not transfected
cells in the presence of
8-Br-cAMP. c Cholesterol efflux
to 100 μg/ml HDL for 6 h
at 37°C in the presence or
absence of 10 μM CsA in cells
stimulated with or without
0.3 mM 8-Br-cAMP. d Choles-
terol efflux to 28 μg/ml apoA-I
as described in c for HDL. e
Choline efflux to HDL and f
apoA-I as described above for
cholesterol. Single asterisk P<
0.05, triple asterisk P<0.001
compared with cells treated in
the absence of 8-Br-cAMP,
pound sign P<0.01, ns not
significantly different compared
with cells treated in the presence
of 8-Br-cAMP
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binding capacity, it is important to note that SR-BI has a
known preference for lipidated apoA-I and HDL rather than
lipid-free apoA-I [36, 53]. In agreement with this, reduction
in SR-BI expression, either by lipid loading with acLDL
or by stimulation with 8-Br-cAMP (Fig. 3) or by specific
siRNA transfection (Fig. 4), significantly reduces HDL
binding but has no effect on apoA-I binding, cell association
and internalisation (data not shown). On the other hand,
reduction in ABCA1 expression by the use of specific
shRNA affects the interactions with apoA-I (Fig. 5) but does
not modulate HDL interactions (data not shown). The effect
of ABCA1 silencing on apoA-I cell association and inter-
nalisation became most prominently visible after stimulation
with 8-Br-cAMP. In addition, while treatment of macro-
phages with acLDL or 8-Br-cAMP suppresses SR-BI expres-
sion, these stimulations increase ABCA1 expression as well
as apoA-I cell association and internalisation (Fig. 6). There-
fore, these findings not only suggest that HDL and apoA-I
are interacting with distinct receptors, namely, SR-BI and
ABCA1, but also that the interaction might be of specific
importance under different conditions of altered cholesterol
homeostasis. Moreover, it has been shown that also the
relative proportions of lipid-free apolipoproteins and mature
HDL in the plasma can affect the relative activities of
ABCA1- and SR-BI-mediated cholesterol efflux [54, 55].
Whether ABCA1 mediates the binding of apoA-I direct-
ly and hence has to be considered as a receptor is still
unclear. Overexpression of ABCA1 has been shown to
increase apoA-I binding to the cell surface [13]. The direct
interaction of apoA-I with ABCA1 is further supported by
the study of both ABCA1 and apoA-I mutants. All ABCA1
mutants, except ABCA1(WS590S), which fail to promote
cholesterol efflux also fail to cross-link apoA-I [15, 56].
Finally, apoA-I cross-linking to ABCA1 is possible only at
room temperature [15]. We assessed the role of ABCA1 in
apoA-I binding by using shRNA-mediated silencing.
ABCA1 expression is reduced by about 50% on the mRNA
level leading to a slightly lowered apoA-I binding (data
not shown) compared to the more significant reduction in
apoA-I cell association. This result clearly demonstrates
the limitation of this approach especially for binding stud-
ies where the substantial residual ABCA1 activity still
allows significant apoA-I binding. CsA has been shown to
sequester ABCA1 on the cell surface [30]. In this paper,
we observed that treating the cells with CsA indeed cap-
tures ABCA1 on the cell surface and in parallel increases
apoA-I binding (Fig. 7a, b). Thus, these results provide addi-
tional evidence that ABCA1 can serve as a direct apoA-I
binding protein. Moreover, apoA-I internalisation is reduced
by CsA in 8-Br-cAMP stimulated cells. This observation
well explains the observed reduction in apoA-I cell asso-
ciation in these cells and sustains the critical role of ABCA1
for apoA-I internalisation.
Our efflux studies finally reproduced previous findings
that ABCA1 expression modulates cholesterol efflux to
apoA-I but not to HDL (Fig. 8; reviewed in [57]). In addi-
tion, cholesterol and phospholipid efflux to apoA-I are
inhibited whenever apoA-I internalisation is blocked, while
lipid efflux to HDL is not affected. These data support the
hypothesis of an ABCA1-dependent cholesterol efflux to
apoA-I which involves internalisation of the ligand and
probably resecretion of the lipidated particle, i.e. retroendo-
cytosis. Indeed, several other studies are consistent with the
need for endocytosis for lipid efflux to occur [38, 41, 58].
However, it is important to note that cholesterol efflux to
apoA-I may also occur independently of apoA-I inter-
nalisation, suggesting that a more complex regulatory
mechanism underlies this process. It might well be that
apoA-I internalisation is needed to mediate cholesterol ef-
flux from distinct intracellular cholesterol pools.
In summary, our study compares the interaction of HDL
and apoA-I with macrophages.While HDL binds to the cells,
for example via SR-BI, without being further internalised,
apoA-I binding, cell association and internalisation correlate
with ABCA1 expression. The expression and regulation of
these two receptors ensures that both lipid-free apoA-I and
HDL can remove excess cholesterol from macrophages un-
der different circumstances. Future work will have to prove
that our findings made in a transformed murine macrophage
cell line are also valid for primary human monocyte-derived
macrophages.
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